Hangzhou Minsheng Healthcare (301507.SZ) obtained the approval for the production of faveline tablets containing tartaric acid.

Hangzhou Minsheng Healthcare (301507.SZ) announced that the company has received the approval and issuance of the Drug Supplementary Application Approval Notice for Tartaric Acid Varenicline Tablets from the National Medical Products Administration. Tartaric Acid Varenicline Tablets are used for smoking cessation in adults. Varenicline is a selective partial agonist of the nicotinic acetylcholine receptor 42 subtype, with high affinity for this receptor in the nervous system. Varenicline binds to the 42 receptor and produces stimulating effects, while also blocking nicotine from binding to this receptor, thus playing a role in smoking cessation.